[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"International Extranodal Lymphoma Study Group (IELSG)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":92},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,54,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100621877","molecular-and-cellular-characterization-of-malt-lymphoma-100621877",false,"NCT07376330","Molecular and Cellular Characterization of MALT Lymphoma","Molecular and Cellular Characterization of MALT Lymphoma Across Anatomical Sites: Integrative Transcriptomic and Epigenetic Approaches","Inclusion Criteria:\n\n1. Male or female adults 18 years or older\n2. Diagnosis of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue on histology after Jan 1st, 2000.\n3. Availability of tumor material from biopsies (either frozen or formalin-fixed paraffin-embedded) (FFPE).\n4. Availability of the baseline and follow-up annotations.\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","OBSERVATIONAL","Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is an slow growing malignancy characterized by marked biological and clinical differences across different anatomical sites.\n\nUsing participants' samples and clinical information, this observational and non-interventional research aims to generate a comprehensive molecular and cellular atlas of MALT lymphoma. The results will enable the identification of biologically meaningful tumor subtypes, microenvironmental niches, and candidate biomarkers with potential relevance for the diagnosis, prognosis, and therapy of MALT lymphoma.",[24],"MALT Lymphoma","NOT_YET_RECRUITING","2026-06-18",{"date":28,"type":29},"2026-06-22","ACTUAL",{"date":31,"type":20},"2026-09",{"date":33,"type":20},"2029-12",{"name":35,"class":36},"International Extranodal Lymphoma Study Group (IELSG)","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":46,"conditions":47,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":49,"startDateStruct":50,"completionDateStruct":51,"leadSponsor":52,"locationsCount":53},"100604302","characterization-of-primary-central-nervous-system-diffuse-large-b-cell-lymphoma-pcns-dlbcl-by-multiomic-approach-100604302","NCT07147751","Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach","Inclusion Criteria:\n\n1. Be an adult immunocompetent patient who received a PCNS-DLBCL diagnosis according to the WHO-HAEM5 criteria between 2018 and 2024.\n2. Availability of formalin-fixed paraffin-embedded (FFPE) diagnostic tumor material.\n3. Availability of the baseline and follow-up annotations\n\nExclusion Criteria:\n\n1. Established immunodeficiency conditions.\n2. Secondary CNS localizations of DLBCL\n3. Transformed DLBCL",{"count":45,"type":20},100,"PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart.\n\nUnderstanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.",[48],"Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL)",{"date":28,"type":29},{"date":31,"type":20},{"date":33,"type":20},{"name":35,"class":36},2,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100493053","integrated-molecular-and-clinical-profiling-to-improve-disease-characterization-and-outcome-prediction-in-nodal-marginal-zone-lymphoma-100493053","NCT05700149","Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma","Inclusion Criteria:\n\n1. Male or female adults 18 years or older\n2. Diagnosis of NMZL on lymph node histology after Jan 1st, 2000\n3. Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve\n4. Availability of the baseline and follow-up annotations\n\nExclusion Criteria:\n\n1\\. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)",{"count":61,"type":20},300,"International retrospective observational cohort study aimed to describe a molecular classification for NMZL.",[64],"Nodal Marginal Zone Lymphoma","RECRUITING",{"date":28,"type":29},{"date":68,"type":29},"2024-04-11",{"date":70,"type":20},"2026-12-31",{"name":35,"class":36},50,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100570839","integrated-molecular-and-clinical-profiling-of-transformed-splenic-marginal-zone-lymphoma-100570839","NCT06712459","Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma","Inclusion Criteria:\n\n1. Adults aged 18 years or older, regardless of the gender;\n2. Diagnosis of HT of SMZL (both at baseline, co-occurring with diagnosis of SMZL, or during the natural history of the disease);\n3. Availability of diagnostic tumor material (either frozen or FFPE) from spleen, lymph node, extra nodal site, peripheral blood or bone marrow collected at the time of histological transformation. Tumor material (either frozen or FFPE), from spleen, peripheral blood or bone marrow, collected at the time of SMZL diagnosis will be also collected, if available;\n4. Availability of the baseline and follow-up annotations.\n\nExclusion Criteria:\n\n* None",{"count":45,"type":20},"Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.",[82],"Transformed Splenic Marginal Zone Lymphoma","2026-01-15",{"date":85,"type":29},"2026-01-16",{"date":87,"type":29},"2025-10-13",{"date":89,"type":20},"2029-03",{"name":35,"class":36},7,""]